


## **Alert** | Health Emergency Preparedness Task Force: Coronavirus Disease 2019



**March 2020** 

## FDA and FTC Warn Companies for Unauthorized Coronavirus Disease 2019 (COVID-19) Claims

On March 6, 2020, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) jointly issued seven warning letters to companies making alleged unauthorized claims related to the prevention or treatment of the Coronavirus Disease 2019 (COVID-19). In addition to issuing the joint warning letters, the FDA issued a press release announcing the actions taken and pages on its website (www.fda.gov) dedicated to COVID-19 issues. The FDA also posted an album of pictures of the alleged fraudulent products being promoted for the treatment or prevention of COVID-19.

In the letters, the FDA reiterated that non-drug products promoted to mitigate, prevent, treat, diagnose, or cure diseases such as COVID-19 are unapproved new drugs in violation of the Federal Food, Drug and Cosmetic Act (FD & C Act). The FDA and the FTC identified information on company websites and social media platforms that allegedly constituted claims for the treatment or prevention of COVID-19. Due to the public health emergency existing nationwide regarding COVID-19, the FDA and the FTC demanded more immediate action than is usually required regarding warning letters. Companies were requested to respond within 48 hours to describe the steps taken to correct the alleged violations; the agencies indicated that failure to do so could result in legal action, including injunction and seizure.

The letters further indicated that, pursuant to the FTC Act, all advertising must be substantiated by competent and reliable scientific evidence. As there are currently no authorized vaccines, pills, potions, lozenges, or other prescription or over-the-counter products available to treat or cure COVID-19, the FTC asserted that there is no competent and reliable scientific information to support any claims. So,



even if it were legal to sell non-drug products to treat COVID-19 under the FD & C Act, which it is not, the claims would not be substantiated either.

The FDA and the FTC have historically demonstrated aggressive action against alleged unauthorized advertising pertaining to pandemic outbreaks. The agencies previously sent joint warning letters to companies promoting products for the unauthorized treatment or prevention of the Ebola virus, the Avian Flu, and SARS (Severe Acute Respiratory Syndrome). The actions by the two agencies should make it clear to companies that the FDA and the FTC will be closely scrutinizing marketing and advertising across all platforms to ensure that no unauthorized claims are made regarding the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.

## **Authors**

This GT Alert was prepared by **Justin J. Prochnow**, **James R. Prochnow**, **Nancy E. Taylor**, and **Michael R. Goodman**. Questions about this information can be directed to:

- Justin J. Prochnow | +1 303.572.6562 | prochnowjj@gtlaw.com
- James R. Prochnow | +1 303.572.6546 | prochnowj@gtlaw.com
- Nancy E. Taylor | +1 202.331.3133 | taylorn@gtlaw.com
- Michael R. Goodman | +1 303.572.6500 | goodmanm@gtlaw.com
- Or your Greenberg Traurig attorney

Albany. Amsterdam. Atlanta. Austin. Boca Raton. Boston. Chicago. Dallas. Delaware. Denver. Fort Lauderdale. Germany.¬ Houston. Las Vegas. London.\* Los Angeles. Mexico City.⁺ Miami. Milan.⁵ Minneapolis. Nashville. New Jersey. New York. Northern Virginia. Orange County. Orlando. Philadelphia. Phoenix. Sacramento. San Francisco. Seoul.™ Shanghai. Silicon Valley. Tallahassee. Tampa. Tel Aviv.^ Tokyo.∗ Warsaw.~ Washington, D.C.. West Palm Beach. Westchester County.

This Greenberg Traurig Alert is issued for informational purposes only and is not intended to be construed or used as general legal advice nor as a solicitation of any type. Please contact the author(s) or your Greenberg Traurig contact if you have questions regarding the currency of this information. The hiring of a lawyer is an important decision. Before you decide, ask for written information about the lawyer's legal qualifications and experience. Greenberg Traurig is a service mark and trade name of Greenberg Traurig, LLP and Greenberg Traurig, P.A. ¬Greenberg Traurig's Berlin office is operated by Greenberg Traurig Germany, an affiliate of Greenberg Traurig, P.A. and Greenberg Traurig, LLP. \*Operates as a separate UK registered legal entity. +Greenberg Traurig's Mexico City office is operated by Greenberg Traurig, S.C., an affiliate of Greenberg Traurig, P.A. and Greenberg Traurig, LLP. \*Greenberg Traurig Santa Maria, an affiliate of Greenberg Traurig, P.A. and Greenberg Traurig, LLP. \*Operates as Greenberg Traurig LLP Foreign Legal Consultant Office. \*Greenberg Traurig's Tel Aviv office is a branch of Greenberg Traurig, P.A., Florida, USA. \*Greenberg Traurig Tokyo Law Offices are operated by GT Tokyo Horitsu Jimusho, an affiliate of Greenberg Traurig, P.A. and Greenberg Traurig, LLP. \*Greenberg Traurig's Warsaw office is operated by Greenberg Traurig Grzesiak sp.k., an affiliate of Greenberg Traurig, P.A. Images in this advertisement do not depict Greenberg Traurig attorneys, clients, staff or facilities. No aspect of this advertisement has been approved by the Supreme Court of New Jersey. ©2020 Greenberg Traurig, LLP. All rights reserved.

© 2020 Greenberg Traurig, LLP www.gtlaw.com | 2